SES cost effective in high-risk patients in Canada

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1551, 2006-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Abciximab for high-risk patients: effective at a cost

By  

Inpharma, Vol. 1, Iss. 1262, 2000-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Abciximab for high-risk patients: effective at a cost

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 287, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

NSAID/PPI pill only cost effective in high-risk RA patients

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 656, 2012-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Iodixanol cost effective vs iohexol among high-risk patients

By  

Inpharma, Vol. 1, Iss. 1482, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of the Sirolimus-Eluting Stent in High-Risk Patients in Canada: An Analysis from the C-SIRIUS Trial

By Rinfret Stéphane  

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 3, 2006-01 ,pp. : 159-168

Adis International

Access to resources Recommend Favorite